1. The role of metabolic reprogramming in pancreatic cancer chemoresistance
   Chang Liu et al, 2023, Frontiers in Pharmacology CrossRef
2. Regulation of protein O-GlcNAcylation by circadian, metabolic, and cellular signals
   Xianhui Liu et al, 2024, Journal of Biological Chemistry CrossRef
3. Structure–activity relationships for the G-quadruplex-targeting experimental drug QN-302 and two analogues probed with comparative transcriptome profiling and molecular modeling
   Ahmed Abdullah Ahmed et al, 2024, Scientific Reports CrossRef
4. Stomatin-like protein 2 deficiency exacerbates adverse cardiac remodeling
   Yuntao Hu et al, 2023, Cell Death Discovery CrossRef
5. GFPT2 expression is induced by gemcitabine administration and enhances invasion by activating the hexosamine biosynthetic pathway in pancreatic cancer
   Kent Miyazaki et al, 2024, Clinical & Experimental Metastasis CrossRef
6. Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib
   Yufeng Liu et al, 2023, Oncogene CrossRef
7. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer
   Hui-Ru Zhang et al, 2024, Cell Death & Disease CrossRef
8. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation
   Cheng Qin et al, 2023, Cell Death & Disease CrossRef
9. The Hexosamine Biosynthesis Pathway: Regulation and Function
   Alysta Paneque et al, 2023, Genes CrossRef
10. Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2) Is Upregulated in Breast Epithelial–Mesenchymal Transition and Responds to Oxidative Stress
    Qiong Wang et al, 2022, Molecular & Cellular Proteomics CrossRef